- Home
- NCPL vs RNAZ Comparison
NCPL vs RNAZ Comparison
Compare NCPL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | RNAZ |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCPL | RNAZ |
|---|---|---|
| Price | $0.69 | $2.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.5M | 29.8K |
| Earning Date | 03-19-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $869,460.00 | N/A |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $2.24 |
| 52 Week High | $2.75 | $20.99 |
Technical Indicators
Market Signals| Indicator | NCPL | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 66.33 | 27.14 |
| Support Level | $0.34 | N/A |
| Resistance Level | $0.60 | $6.15 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 59.88 | 2.01 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.